Synthesis and anti-platelet aggregation activity evaluation of ligustrazine derivatives was written by Fan, Lingling;Li, Yi;Wu, Xiaofang;Li, Yong;Zhang, Jue. And the article was included in Huaxue Tongbao in 2018.Safety of (3,5,6-Trimethylpyrazin-2-yl)methanol This article mentions the following:
Using ligustrazine (TMP) and o-phenylenediamine as raw materials, seven derivatives were synthesized via KMnO4 oxidation, esterification, cyclization and reduction The structures were confirmed by 1H NMR, 13C NMR and HRMS. The in vitro anti-platelet aggregation activities of the target compounds have been preliminarily tested by the Born turbidimetric method, and the exptl. results showed that compounds 3 (IC50 = 0.23 mmol/L) and 7 (IC50 = 0.27mmol/L) have significant inhibitory activity of against ADP (ADP) induced platelet aggregation, higher than that of ligustrazine (IC50 = 0.42mmol/L). In the experiment, the researchers used many compounds, for example, (3,5,6-Trimethylpyrazin-2-yl)methanol (cas: 75907-74-3Safety of (3,5,6-Trimethylpyrazin-2-yl)methanol).
(3,5,6-Trimethylpyrazin-2-yl)methanol (cas: 75907-74-3) belongs to pyrazine derivatives. Pyrazines are part of several biologically active polycyclic compounds; examples are quinoxalines, phenazines; and the bio-luminescent natural products pteridines, flavins, and their derivatives. Pyrazines undergo nearly all of the same reactions as pyrimidines, from nucleophilic substitution (SNAr) to palladium-catalyzed cross coupling reactions.Safety of (3,5,6-Trimethylpyrazin-2-yl)methanol